If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
221
results.
Updated on
07/08/2025 [07:14:00]
Results 75 to 100 of 221
Absstract of: US2025242032A1
Provided in the present invention are an aggregate and a preparation method therefor, and an insulin oral preparation. Specifically provided is an aggregate, which is an aggregate formed by means of assembling a chalcogen heterocyclic compound and insulin. The aggregate can be further prepared into an insulin oral preparation. The oral preparation can be used for reducing the blood glucose level of a mammal as part of a diabetes treatment regimen. The chalcogen heterocyclic compound in the insulin oral preparation prepared by means of the method can effectively protect insulin against the three physiological barriers of an oral uptake pathway, is stable in the gastrointestinal tract environment, is subjected to a dynamic chemical exchange reaction with intestinal mucin in intestinal juice and the sulfhydryl groups of proteins inside and outside an epithelial cell membrane by means of the molecular bond of polychalcogen on the surface, and enters the circulation system from the intestinal epithelial cell to achieve the effect of reducing blood glucose. When being orally administered, the insulin oral preparation has high bioavailability, has a good hypoglycemic effect in mammals, and can be used for treating diabetes.
Absstract of: US2025242030A1
Disclosed herein are compositions comprising a polymer and a metabolic inhibitor, as well as a method of using the composition to modulate an immune response. The composition may be produced in the form of a synthetic tissue for provision in a subject. The composition or synthetic tissue may further comprise additional therapeutic agents.
Absstract of: WO2025160381A1
The present disclosure provides methods of preparing lipid nanoparticle (LNP) formulations. The present disclosure also provides therapeutic and diagnostic uses related to the prepared LNP formulations.
Absstract of: WO2025160127A1
The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles include a novel ionizable lipid as well as additional lipids such as cationic lipids, phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Absstract of: WO2025160452A1
Provided herein are methods to treat various neurodegenerative disorders comprising delivering a viral particles to the whole brain, including both superficial and deep structures. In some aspects, the viral particles are administered at low dose levels to the CSF, in conjunction with microbubbles followed by application of focused ultrasound (FUS) to a region of interest of the brain, thereby causing entry of the viral particles to the brain.
Absstract of: US2025242045A1
Disclosed herein are cell-targeting complexes that are coated on the surface with target specific antibodies for induction of biological stimulus in target cells/tissue/organs. In some embodiments, the cell-targeting complex involves non-nucleated (e.g. platelets, red blood cells (RBC)) or enucleated cells that have been thiolated, streptavidinylated, and then coated with biotinylated antibodies. In some embodiments, the cell-targeting complex involves multilayer alginate hydrogel beads that have been coated with polyanionic proteins using a polycation, which is then thiolated, streptavidinylated, and then coated with biotinylated antibodies.
Absstract of: US2025242015A1
The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-E1-A-E2-U-H and H-U-E1-A-E2-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.
Absstract of: US2025242028A1
A metal boride nanoparticle is provided, which has dual functions of tumor diagnosis and therapeutic treatment. A surface of the metal boride nanoparticle is modified with antibodies, bioprobes, or coated with a biological cell membrane, and the antibodies or the bioprobes have a specificity for binding to receptors on specific tumor cells.
Absstract of: US2025241943A1
The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
Absstract of: US2025241863A1
In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.
Absstract of: US2025241848A1
The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.
Absstract of: WO2025157953A1
An ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer of any one of them; a lipid nanoparticle comprising the ionizable lipid, particularly, as an encapsulation agent, optionally comprising a pharmaceutically active agent; and a pharmaceutical composition comprising the lipid nanoparticle. A lipid nanoparticle or a pharmaceutical composition comprising thereof for use in medicine, and the use of the lipid nanoparticles as an encapsulating agent.
Absstract of: WO2025157978A1
The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.
Absstract of: US2025241886A1
The present disclosure relates to a method of preventing or treating brain cancers or brain metastases with mesoporous silica nanoparticles (MSNs) loaded with taxane-based chemotherapeutic drugs, in particular paclitaxel (PTX), cabazitaxel (CTX) or docetaxel (DTX), and the MSNs loaded with PTX, CTX or DTX.
Absstract of: US2025241858A1
The present disclosure provides unshielded lipid nanoparticles and a process that enables the production of such unshielded lipid nanoparticles, thereby overcoming previous challenges of making particles without causing aggregation thereof. The lipid nanoparticles comprise a nucleic acid cargo molecule; a sterol or a derivative thereof present at a content of at least 12 mol %; a neutral lipid, such as a phospholipid having a choline head group present at a content of between 22 mol % and 65 mol %; and an ionizable cationic amino lipid present at a content of between 15 mol % and 45 mol %; wherein the lipid nanoparticle is non-sterically stabilized with a hydrophilic polymer-lipid conjugate, or otherwise unshielded and wherein each mol % content is relative to total lipid present in the lipid nanoparticle.
Absstract of: US2025241974A1
Materials and methods for modulating wound healing are described. Compositions including a phenolic acid extract of berries from the Vaccinium family are useful for promoting wound healing, and can be formulated in a cream, a serum or gel, or in a nanocellulose hydrogel.
Absstract of: US2025242059A1
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Absstract of: US2025241866A1
Substances in the form of flexible disks to modulate mechanotransduction mediated by integrins were designed. Two main ideas for the design are as follows. First, the radius of the disk can be prescribed to specify the radius of mechanically perturbed integrin clusters. By using disks with a greater radius value, the vinculin binding site activation vs. force relation can be amplified and shifted to the positive direction along the input axis. Second, by recruiting a certain integrin whose affinity values to talins are higher than those of other integrins into the cluster, the radial distance from the center of clusters to the point where the membrane tightly adheres to the cytoskeleton can be decreased. This results in the increase of the maximum slope of the vinculin binding site activation vs. force relation. The design can be used in the development of drugs for diseases associated with dysfunctions in integrin-mediated systems.
Absstract of: US2025241865A1
Nanoparticles useful for drug delivery are described. In one aspect, the nanoparticles contain poly(amine-co-ester)s or poly(amine-co-amide)s (PACE) modified with poly(ethylene glycol) (PACE-PEG), and can be optionally blended with a second PACE polymer optionally containing endgroup modifications. In another aspect, the nanoparticles contain a core containing a PACE polymer optionally containing endgroup modifications, and a polymeric surfactant non-covalently conjugated to the surface of the nanoparticles. The nanoparticles contain a peptide or protein targeting moiety that is covalently conjugated to the PACE-PEG polymer or to the surfactant on the surface of the nanoparticles via a linkage that contains a succinimide or substituted sulfone moiety, respectively. The nanoparticles provide as a versatile platform for the delivery of nucleic acids, such as mRNA.
Absstract of: US2025241854A1
Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.
Absstract of: US2025241985A1
Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of stroke.
Absstract of: US2025241999A1
Systems for enhanced delivery of functional, recombinant soluble uricase enzymes with long serum residence, low immunogenicity and potential for modification have been developed. Compositions and methods of use thereof of nanoparticles including recombinant soluble uricase enzymes are provided for oral administration to a subject. The nanoparticle compositions include recombinant soluble uricase enzymes that are not PEGylated, and have a serum residence time of hours, days or weeks following oral administration. A reduced level of side effects of the formulation provides an effective and safe drug delivery platform for treating Tumor Lysis syndrome and Lesch-Nyhan disease, as well as hyperuricemia and associated diseases or disorders.
Absstract of: US2025241864A1
Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
Absstract of: WO2025159693A1
The present disclosure provides a lipid nanoparticle comprising a helper lipid at about 5 mol% to about 80 mol% relative to a total lipid content; an ionisable lipid at about 20 mol% to about 95 mol% relative to the total lipid content; a conjugated oligoelectrolyte at about 0.005 mol% to about 5 mol% relative to the total lipid content, wherein the conjugated oligoelectrolyte is configured to interact with at least the helper lipid in order 10 to stabilise the lipid nanoparticle. The present disclosure also provides methods of fabricating the lipid nanoparticle and methods of use thereof.
Nº publicación: US2025243151A1 31/07/2025
Applicant:
ACER INCORPORATED [TW]
Acer Incorporated
Absstract of: US2025243151A1
An ionizable lipid having a structure represented by the following formula (I):wherein Y is independently selected from a group consisting of —NH—, —O—, —S—, and a single bond; X is independently selected from —NR1R2 or a nitrogen-containing heteroaryl group; L1 and L2 are each independently selected from a group consisting of a C1-C10 alkylene group, a C2-C10 alkenylene group,R1 and R2 are each independently selected from a group consisting of H, a substituted or unsubstituted C1-C10 hydrocarbyl group, a substituted or unsubstituted C1-C10 heterohydrocarbyl group, a substituted or unsubstituted C6-C20 aryl group, and a substituted or unsubstituted C1-C20 heteroaryl group; R3 is a C5-C30 alkyl group; R4 is a C5-C30 alkyl group; n is an integer selected from 1 to 10; and m and p are each independently an integer selected from 1 to 20.
BOPI
Electronic site
